Literature DB >> 11753614

Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts.

K U Birkenkamp1, M Geugien, H H Lemmink, W Kruijer, E Vellenga.   

Abstract

In the present study, we examined the underlying mechanism, which causes the constitutive tyrosine phosphorylation of signal transducer and activator of transcription 5 (STAT5) in acute myeloid leukemia (AML) blasts. Constitutive STAT5 phosphorylation was observed in 18 of 26 (69%) patients with AML. The constitutive STAT5 phosphorylation was caused by different mechanisms. In the majority of the investigated cases (71% (12 of 17)) constitutive STAT5 phosphorylation was associated with autophosphorylation of the type III receptor tyrosine kinase Flt3. In 47% (eight of 17) of these cases autophosphorylation of Flt3 coincided with tandem duplications of the Flt3 gene, resulting in constitutive phosphorylation of the receptor, while 24% (four of 17) of the cases demonstrated STAT5 phosphorylation and Flt3 autophosphorylation without mutations. In addition, a subset of AML cases (29% (five of 17)) had no autophosphorylation of the Flt3 receptor, but demonstrated constitutive STAT5 phosphorylation, which was partly due to autocrine growth factor production. All AML cases with high STAT5 and Flt3 phosphorylation demonstrated, in general, a lower percentage of spontaneous apoptosis, compared to AML blasts with no spontaneous STAT5 phosphorylation. Addition of the receptor tyrosine III kinase inhibitor AG1296 strongly inhibited STAT5 phosphorylation and enhanced the percentage of apoptotic cells without modulating the Bcl-xl protein levels. These data indicate that in the majority of AML cases the constitutive STAT5 phosphorylation is caused by Flt3 phosphorylation mostly due to mutations in the receptors and associated with a low degree of spontaneous apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11753614     DOI: 10.1038/sj.leu.2402317

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  39 in total

1.  Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.

Authors:  Xiaoyang Li; Yuqi Jiang; Yuri K Peterson; Tongqiang Xu; Richard A Himes; Xin Luo; Guilin Yin; Elizabeth S Inks; Nathan Dolloff; Stephanie Halene; Sherine S L Chan; C James Chou
Journal:  J Med Chem       Date:  2020-05-06       Impact factor: 7.446

2.  Targeted blockage of signal transducer and activator of transcription 5 signaling pathway with decoy oligodeoxynucleotides suppresses leukemic K562 cell growth.

Authors:  Xiaozhong Wang; Jianming Zeng; Mei Shi; Shiqiao Zhao; Weijun Bai; Weixi Cao; Zhiguang Tu; Zonggan Huang; Wenli Feng
Journal:  DNA Cell Biol       Date:  2010-11-22       Impact factor: 3.311

3.  RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.

Authors:  Jeffrey W Tyner; Denise K Walters; Stephanie G Willis; Mary Luttropp; Jason Oost; Marc Loriaux; Heidi Erickson; Amie S Corbin; Thomas O'Hare; Michael C Heinrich; Michael W Deininger; Brian J Druker
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

4.  Transforming growth factor-beta downregulates interleukin-2-induced phosphorylation of signal transducer and activator of transcription 5 in human renal cell carcinoma.

Authors:  Cheryn Song; Sun-Young Jun; Jun-Hyuk Hong; Hanjong Ahn
Journal:  J Cancer Res Clin Oncol       Date:  2007-02-06       Impact factor: 4.553

Review 5.  Targeting signal transducer and activator of transcription signaling pathway in leukemias.

Authors:  Mustafa Benekli; Heinz Baumann; Meir Wetzler
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

6.  STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2.

Authors:  Winnie F Tam; Patricia S Hähnel; Andrea Schüler; Benjamin H Lee; Rachel Okabe; Nan Zhu; Saskia V Pante; Glen Raffel; Thomas Mercher; Gerlinde Wernig; Ernesto Bockamp; Daniel Sasca; Andreas Kreft; Gertraud W Robinson; Lothar Hennighausen; D Gary Gilliland; Thomas Kindler
Journal:  Cancer Res       Date:  2012-11-13       Impact factor: 12.701

7.  Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.

Authors:  Manoj Garg; Yasunobu Nagata; Deepika Kanojia; Anand Mayakonda; Kenichi Yoshida; Sreya Haridas Keloth; Zhi Jiang Zang; Yusuke Okuno; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Satoru Miyano; Ling-Wen Ding; Tamara Alpermann; Qiao-Yang Sun; De-Chen Lin; Wenwen Chien; Vikas Madan; Li-Zhen Liu; Kar-Tong Tan; Abhishek Sampath; Subhashree Venkatesan; Koiti Inokuchi; Satoshi Wakita; Hiroki Yamaguchi; Wee Joo Chng; Shirley-Kow Yin Kham; Allen Eng-Juh Yeoh; Masashi Sanada; Joanna Schiller; Karl-Anton Kreuzer; Steven M Kornblau; Hagop M Kantarjian; Torsten Haferlach; Michael Lill; Ming-Chung Kuo; Lee-Yung Shih; Igor-Wolfgang Blau; Olga Blau; Henry Yang; Seishi Ogawa; H Phillip Koeffler
Journal:  Blood       Date:  2015-10-05       Impact factor: 22.113

8.  Parallel analysis of transcript and translation profiles: identification of metastasis-related signal pathways differentially regulated by drug and genetic modifications.

Authors:  Haiyan Yang; Li-Rong Yu; Ming Yi; David A Lucas; Luanne Lukes; Mindy Lancaster; King C Chan; Haleem J Issaq; Robert M Stephens; Thomas P Conrads; Timothy D Veenstra; Kent W Hunter
Journal:  J Proteome Res       Date:  2006-07       Impact factor: 4.466

9.  Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.

Authors:  Anupriya Agarwal; Ryan J MacKenzie; Raffaella Pippa; Christopher A Eide; Jessica Oddo; Jeffrey W Tyner; Rosalie Sears; Michael P Vitek; María D Odero; Dale J Christensen; Brian J Druker
Journal:  Clin Cancer Res       Date:  2014-01-16       Impact factor: 12.531

10.  Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses.

Authors:  Lina Han; Albertus T J Wierenga; Marjan Rozenveld-Geugien; Kim van de Lande; Edo Vellenga; Jan Jacob Schuringa
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.